{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:15:21Z","timestamp":1792066521246,"version":"4.4.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A new type of regulated cell death known as Necrosis by Sodium Overload (NECSO) has been discovered recently. There is growing evidence indicating that NECSO is essential in both anti-tumor immune responses and the proliferation of cancer cells. Nonetheless, the underlying mechanisms and clinical relevance of NECSO are still not well understood, especially regarding its prognostic significance in kidney renal clear cell carcinoma (KIRC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We utilized Non-negative Matrix Factorization (NMF) to distinguish unique NECSO patterns derived from NECSO-associated genes within the TCGA dataset, which led to the identification of three distinct subgroups. Furthermore, we created an innovative NECSO score (NECSOS) utilizing machine learning techniques and confirmed its clinical relevance through validation in several independent datasets, which comprised one transcriptomic cohort of immune checkpoint inhibitor (ICI)-treated KIRC patients, three pan-cancer ICI-treated cohorts, two single-cell RNA sequencing datasets of KIRC patients, and one single-cell dataset from patients treated with PD-1 inhibitors. To characterize FLAD1, we performed gain- and loss-of-function assays for proliferation, migration, and invasion, sodium overload (NC1) sensitivity assays, subcutaneous xenograft models, and CD8+ T cell co-culture cytokine profiling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The genetic landscape and immune microenvironment of these subgroups were thoroughly characterized, uncovering important insights into the heterogeneity of the tumor microenvironment (TME) and its response to immunotherapy. The NECSO model we developed exhibited strong predictive accuracy for prognosis and immunotherapy responses in patients with KIRC, with validation conducted in diverse pan-cancer ICI cohorts. FLAD1 was identified as a novel prognostic biomarker, and its oncogenic roles in proliferation, migration, and invasion were experimentally confirmed. Mechanistically, FLAD1 regulated cellular sensitivity to TRPM4-mediated sodium overload, promoted tumor growth\n                      <jats:italic>in vivo<\/jats:italic>\n                      , and modulated the secretion of T cell-recruiting chemokines and pro-inflammatory cytokines, positioning it as a mechanistic driver within the NECSO-immunity axis rather than merely a prognostic marker.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study has established a robust NECSO-based classification system and prognostic model for KIRC while identifying FLAD1 as a novel biomarker and functional driver of the necrosis-immunity axis. These integrated approaches provide clinically actionable tools for predicting patient outcomes and immunotherapy efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1914332","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:22:28Z","timestamp":1785219748000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["NECSO-based classification predicts immunotherapy efficacy and identifies FLAD1 as therapeutic target in kidney renal clear cell carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Yitong","family":"Pan","sequence":"first","affiliation":[{"name":"Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University","place":["Changsha, Hunan, China"]},{"name":"Furong Laboratory, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wu","sequence":"additional","affiliation":[{"name":"Computation Biology Department, China National Center for Bioinformation","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Institute of Integrated Traditional Chinese and Western Medicine, Huashan Hospital Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodi","family":"Hu","sequence":"additional","affiliation":[{"name":"Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingwen","family":"Kong","sequence":"additional","affiliation":[{"name":"Institute of Integrated Traditional Chinese and Western Medicine, Huashan Hospital Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.eururo.2019.02.011","article-title":"European association of urology guidelines on renal cell carcinoma: the 2019 update","volume":"75","author":"Ljungberg","year":"2019","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/jop.2016.019620","article-title":"Management of small renal masses: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Finelli","year":"2017","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s12032-018-1217-1","article-title":"Contemporary treatment of metastatic renal cell carcinoma","volume":"35","author":"Wiechno","year":"2018","journal-title":"Med Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0337-2","article-title":"The future of cancer immunotherapy: microenvironment-targeting combinations","volume":"30","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmcibr1914890","article-title":"Tumor microenvironment, metabolism, and immunotherapy","volume":"382","author":"DeBerardinis","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-022-00272-w","article-title":"Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance","volume":"6","author":"Ge","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41392-022-01110-y","article-title":"Regulated cell death (RCD) in cancer: key pathways and targeted therapies","volume":"7","author":"Peng","year":"2022","journal-title":"Signal Transduction Targeted Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-025-01841-3","article-title":"Persistent activation of TRPM4 triggers necrotic cell death characterized by sodium overload","volume":"21","author":"Fu","year":"2025","journal-title":"Nat Chem Biol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41467-025-67181-x","article-title":"Sodium disrupts mitochondrial energy metabolism to execute NECSO","volume":"17","author":"Qiao","year":"2025","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1623511","article-title":"Necrosis by sodium overload-associated genes TRPM4 and SLC9A1: biological roles and clinical implications in breast cancer progression","volume":"16","author":"Zhu","year":"2025","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s10142-025-01674-2","article-title":"Construction of a prognostic model for hepatocellular carcinoma based on necrosis by sodium overload-related genes and identification of ANKRD13B as a new prognostic marker","volume":"25","author":"Qu","year":"2025","journal-title":"Funct Integr Genomics"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma","volume":"26","author":"Braun","year":"2020","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-22-1417","article-title":"Characterization of immune-related alternative polyadenylation events in cancer immunotherapy","volume":"82","author":"Wang","year":"2022","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1038\/s41467-019-12159-9","article-title":"DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load","volume":"10","author":"Jung","year":"2019","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41467-017-02391-6","article-title":"Perturbation-response genes reveal signaling footprints in cancer gene expression","volume":"9","author":"Schubert","year":"2018","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202512627","article-title":"PBRM1 deficiency reshapes an immune suppressive microenvironment through epigenetic tuning of PBRM1\u2010KDM5C\u2010IL6 axis in ccRCC","volume":"13","author":"Xia","year":"2026","journal-title":"Adv Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.01.005","article-title":"Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold","volume":"178","author":"Vredevoogd","year":"2019","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03235-6","article-title":"Lipid signalling enforces functional specialization of Treg cells in tumours","volume":"591","author":"Lim","year":"2021","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao1710","article-title":"A major chromatin regulator determines resistance of tumor cells to T cell\u2013mediated killing","volume":"359","author":"Pan","year":"2018","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13073-022-01050-w","article-title":"Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response","volume":"14","author":"Zhang","year":"2022","journal-title":"Genome Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nature23270","article-title":"In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target","volume":"547","author":"Manguso","year":"2017","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/s41467-025-56458-w","article-title":"Copy number amplification of FLAD1 promotes the progression of triple-negative breast cancer through lipid metabolism","volume":"16","author":"Song","year":"2025","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"9547","DOI":"10.1038\/s41467-025-64572-y","article-title":"FAD synthase confers ferroptosis resistance and restrains CD8+ T cell recruitment in hepatocellular carcinoma","volume":"16","author":"Chao","year":"2025","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/bs.ai.2015.12.002","article-title":"Immune contexture, immunoscore, and Malignant cell molecular subgroups for prognostic and theranostic classifications of cancers","volume":"130","author":"Becht","year":"2016","journal-title":"Adv Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00466-1","article-title":"Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities","volume":"22","author":"Laumont","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.04.011","article-title":"Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101621","article-title":"Advances and prospects of biomarkers for immune checkpoint inhibitors","volume":"5","author":"Yamaguchi","year":"2024","journal-title":"Cell Rep Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/cac2.12138","article-title":"EMT\u2010associated microRNAs and their roles in cancer stemness and drug resistance","volume":"41","author":"Pan","year":"2021","journal-title":"Cancer Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","article-title":"Targeting mutant p53 for cancer therapy: direct and indirect strategies","volume":"14","author":"Hu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1914332\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:22:29Z","timestamp":1785219749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1914332\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2026.1914332"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1914332","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1914332"}}